id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-342625-31fe1neb	Baba, Hiroaki	Prolonged presence of SARS-CoV-2 in a COVID-19 case with rheumatoid arthritis taking iguratimod treated with ciclesonide	2020-07-01		.txt	text/plain	1457	76	48	The patient who continued iguratimod therapy without dose reduction was treated with ciclesonide had an uneventful clinical course, but prolonged detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was observed after resolution of symptoms. The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the world, yet investigations of in patients with rheumatologic disease taking disease-modifying antirheumatic drugs (DMARDs) with immunomodulatory or immunosuppressive effects remain scarce [1] . Here we report a case of COVID-19 in a patient with rheumatoid arthritis taking iguratimod, who had prolonged viral RNA presence. A woman in her 40s with rheumatoid arthritis treated with iguratimod 25 mg twice a day was admitted to Tohoku University Hospital, Sendai, Japan, with a diagnosis of COVID-19 based on real-time reverse transcription polymerase chain reaction (real-time RT-PCR) with primers that target the N2 gene of SARS-CoV-2 as described previously [2] from nasopharyngeal swabs and sputum.	./cache/cord-342625-31fe1neb.txt	./txt/cord-342625-31fe1neb.txt